Hansa Biopharma — Juni 2023
-
Sarepta Therapeutics Trading Halts
-
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
-
FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy
-
FDA approves $3.2 million gene therapy for rare muscular dystrophy in kids ages 4 and 5
FDA approves $3.2 million gene therapy for rare muscular dystrophy in kids ages 4 and 5 | CNN
The US Food and Drug Administration approved the first gene therapy to treat a rare and devastating muscle disease, but limited the approval to kids ages four and five based on currently available evidence.
CNN (edition.cnn.com)
(CNN Health)
Serepta får godkendt genterapi og sætter prisen til 22 mio. kr.
Serepta får godkendt genterapi og sætter prisen til 22 mio. kr.
Genterapien har været igennem en langvarig proces hos de amerikanske myndigheder.
(medwatch.dk)
(Medwatch)
-
Kan ikke gi' en god forklaring men der er kommet nye kursmål ...
Fx: "Citigroup Adjusts Sarepta Therapeutics' Price Target to $161 From $204, Maintains Buy Rating"
-
lad os så komme gennem 50 og 60 og så blive over og ikke som de sidste 12 mdr. hvor den er dykket ned igen omkring 50 og under 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind